Catalyst Pharmaceutical has received a Nasdaq staff deficiency letter indicating it is not in compliance with the minimum bid price requirement of rule 5550a2 for continued listing. Based on the last 30 consecutive business days closing bid price, the company has not maintained a minimum bid price of $1 per share. Catalyst has a grace period of 180 calendar days in which to ensure that its security bid price closes at or above $1.00 per share for a minimum of ten consecutive business days, so that it can regain compliance and close this matter. The Company understands the Nasdaq requirements and believes it will be able to regain compliance within the grace period. :theflyonthewall.com
News For CPRX From The Last 14 Days
Check below for free stories on CPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
